New Research Examines Long-Term Migraine Prevention as Advances in Targeted Treatments Offer Hope to Millions

New research from South Korea is adding important real-world evidence to the growing field of migraine prevention, examining the safety and effectiveness of fremanezumab, a targeted treatment designed to block a protein involved in migraine attacks. A three-year interim analysis involving more than 1,200 patients found meaningful reductions in monthly migraine days, with over half experiencing at least a 50% improvement after 12 weeks. The findings highlight the potential of targeted therapies while underscoring the need for longer-term patient monitoring.

Migraine is increasingly becoming a significant global healthcare concern, affecting millions of people and disrupting their ability to work, study and maintain everyday routines. While occasional headaches are common, migraine is a complex neurological condition that can cause severe head pain, nausea, sensitivity to light and sound, visual disturbances and, in some cases, prolonged episodes that interfere with daily functioning.

As researchers continue searching for more effective ways to prevent recurring migraine attacks, new findings from South Korea are drawing attention to the potential of targeted therapies. A three-year interim analysis of a real-world clinical study has provided encouraging evidence on the safety and effectiveness of fremanezumab, a preventive medication designed to target a biological pathway associated with migraine.

Published in the medical journal Drugs – Real World Outcomes in July 2026, the research evaluated patients receiving fremanezumab in routine clinical practice across South Korea. The study included safety data from 1,230 adults and effectiveness data from 1,096 participants, making it an important contribution to the understanding of how migraine-specific treatments perform outside controlled clinical trials.

The research forms part of an ongoing six-year, prospective, non-interventional post-marketing surveillance program that began in July 2021 and is expected to continue through July 2027. The three-year interim analysis examined data collected from 14 participating medical centers and hospitals, offering insights into treatment outcomes among patients with both episodic and chronic migraine.

One of the most notable findings was the reduction in the number of monthly migraine days following treatment. Among participants included in the effectiveness analysis, the average number of migraine days decreased from 16.5 days at baseline to 8.7 days after 12 weeks of treatment. This represented an average reduction of 7.8 migraine days per month.

More than half of the participants also experienced a substantial improvement in migraine frequency. Approximately 56.5% achieved at least a 50% reduction in their monthly migraine days, while 26.8% experienced a reduction of at least 75%. Researchers reported improvements in both episodic and chronic migraine groups, with particularly notable reductions among patients experiencing chronic migraine.

The findings are significant because chronic migraine can impose a considerable burden on patients, often affecting their professional responsibilities, personal relationships, sleep and overall quality of life. For people experiencing frequent attacks, reducing the number of migraine days can represent an important improvement in daily functioning.

Fremanezumab belongs to a class of medications known as calcitonin gene-related peptide (CGRP) monoclonal antibodies. CGRP is a protein involved in the biological processes associated with migraine attacks, including pain signaling and changes in blood vessel activity. By targeting the CGRP molecule, fremanezumab helps prevent it from activating its receptor and contributing to migraine-related processes.

Unlike conventional pain-relief medications, which are generally used to manage an attack after it begins, fremanezumab is designed as a preventive treatment. It is administered through injection and is available in monthly and quarterly dosing schedules, depending on the approved treatment regimen.

The growing interest in CGRP-targeted medications reflects a broader shift in migraine management. For decades, preventive treatment options often relied on medications originally developed for other conditions, including certain blood pressure medications, antidepressants and anti-seizure drugs. Although these treatments have helped many patients, their effectiveness and tolerability can vary.

Migraine-specific therapies have introduced another approach by targeting biological mechanisms more directly associated with the condition. Fremanezumab is among the treatments developed to address this pathway, alongside other CGRP-targeting medications.

Safety was another important component of the South Korean study. Among the 1,230 participants included in the safety analysis, 17.6% reported adverse events during the 12-week observation period. Injection-site reactions were the most frequently reported side effect, affecting 5.7% of participants. Serious adverse events were reported in approximately 1% of patients.

The researchers concluded that fremanezumab was generally well tolerated in the participating population, with no new safety concerns identified in the interim analysis. However, as with all prescription medications, individual responses and potential side effects require medical evaluation and appropriate monitoring.

Patient-reported outcomes also provided encouraging results. Approximately 87% of participants rated their treatment as effective according to the Patient Global Impression of Change scale, suggesting that many experienced a noticeable improvement in their overall condition.

Beyond the South Korean findings, international research is also examining whether the benefits of fremanezumab can be maintained over extended treatment periods. Results from the European PEARL observational study, presented at the 19th European Headache Congress in 2026, included 1,140 participants followed for up to 24 months. Among those with available effectiveness data, 56.5% achieved at least a 50% reduction in monthly migraine days during the first six months after starting treatment. The study also reported that improvements were maintained across the 24-month observation period.

These findings add another dimension to the discussion surrounding long-term migraine prevention. However, researchers emphasize the importance of interpreting different studies according to their design, patient populations and observation periods.

In particular, the South Korean study's three-year designation refers to the interim period of the overall surveillance program, not three years of continuous treatment observation for every participant. Individual treatment outcomes were assessed over approximately 12 weeks. The findings therefore provide valuable real-world evidence of early treatment effectiveness and tolerability, rather than definitive proof of three-year effectiveness in individual patients.

Despite these encouraging developments, migraine remains a complicated neurological condition with no single preventive treatment that works for everyone. Patients may respond differently depending on their medical history, migraine frequency, other health conditions and previous treatment experiences.

Researchers also acknowledge that observational studies have limitations. Because participants were treated in routine clinical practice rather than randomly assigned to treatment and control groups, the results cannot establish that fremanezumab alone caused every improvement. The use of other migraine medications and differences in patient characteristics may also influence outcomes.

Another important consideration is accessibility. Advanced migraine-specific treatments can be expensive, and availability varies across countries and healthcare systems. Insurance coverage, treatment eligibility and access to specialist neurological care may determine whether patients can benefit from these developments.

Nevertheless, the growing body of evidence surrounding CGRP-targeted therapies represents an important development in neurological research. As more patients gain access to migraine-specific preventive treatments, healthcare professionals are increasingly able to consider treatment approaches based on individual needs rather than relying exclusively on traditional preventive medications.

The next phase of research will be particularly important in establishing how these treatments perform over longer periods, whether their benefits remain consistent, and which patient groups are most likely to experience meaningful improvements. Continued monitoring will also help researchers better understand treatment discontinuation, long-term tolerability and the impact on patients' quality of life.

For millions of people living with recurring migraine attacks, even a moderate reduction in the frequency and severity of episodes can make a meaningful difference. Improved prevention could help patients regain control over their daily routines, reduce interruptions to professional and personal commitments, and improve their overall well-being.

The latest findings from South Korea do not represent a cure for migraine, but they provide encouraging evidence supporting the continued development of targeted preventive treatments. As international research advances, the focus is shifting beyond simply treating migraine attacks toward reducing their frequency, improving long-term disease management and helping patients achieve a better quality of life.

With further clinical evidence, improved access to specialist treatments and continued innovation in neurological medicine, targeted migraine prevention could become an increasingly important part of modern headache care.

For questions or comments write to contactus@bostonbrandmedia.com